Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed agai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Hoffmann, Frank, Richter, Stephan, Engelmann, Ulrich, White, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/
https://www.ncbi.nlm.nih.gov/pubmed/34421780
http://dx.doi.org/10.3389/fneur.2021.620758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/
https://www.ncbi.nlm.nih.gov/pubmed/34421780
http://dx.doi.org/10.3389/fneur.2021.620758

Ejemplares similares